

Company Number: 315082

JMR Pharma Engineering Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 December 2025

JMR Pharma Engineering Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Responsibilities Statement	4
Balance Sheet	5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 10

JMR Pharma Engineering Limited

DIRECTORS AND OTHER INFORMATION

Directors	John Ridgway Adelle Minehane
Company Secretary	Fenaro Tempsec Limited (Appointed 30 January 2025) John Ridgway
Company Number	315082
Registered Office and Business Address	Ballady Belgooly Co. Cork
Accountants	TGS Ireland GBW Chartered Certified Accountants Westmoreland House Westmoreland Park Ranelagh Dublin 6
Bankers	Permanent TSB 1 Curraheen Road Bishopstown Cork

JMR Pharma Engineering Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to TGS Ireland GBW, (Chartered Certified Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 December 2025."

Signed on behalf of the board

John Ridgway

John Ridgway
Director

27 March 2026

Adelle Minehane

Adelle Minehane
Director

27 March 2026

JMR Pharma Engineering Limited

BALANCE SHEET

as at 31 December 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	6	42,375	27,974
Current Assets			
Debtors	7	33,091	24,327
Cash and cash equivalents		51,073	15,311
		84,164	39,638
Creditors: amounts falling due within one year	8	(72,778)	(38,340)
Net Current Assets		11,386	1,298
Total Assets less Current Liabilities		53,761	29,272
Creditors: amounts falling due after more than one year	9	(25,767)	(11,418)
Net Assets		27,994	17,854
Capital and Reserves			
Called up share capital presented as equity		127	127
Retained earnings		27,867	17,727
Equity attributable to owners of the company		27,994	17,854

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of JMR Pharma Engineering Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 27 March 2026 and signed on its behalf by:

John Ridgway

John Ridgway
Director

Adelle Minehane

Adelle Minehane
Director

JMR Pharma Engineering Limited

RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 31 December 2025

	Called up share capital €	Retained earnings €	Total €
At 1 January 2024	127	17,693	17,820
Profit for the financial year	-	34	34
At 31 December 2024	127	17,727	17,854
Profit for the financial year	-	10,140	10,140
At 31 December 2025	127	27,867	27,994

JMR Pharma Engineering Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

1. General Information

JMR Pharma Engineering Limited is a company limited by shares incorporated in Ireland. Ballady, Belgooly, Co. Cork is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Revenue is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Revenue comprises the fair value of consideration received and receivable exclusive of value added tax and after discounts and rebates.

Revenue from the provision of services is recognised in the accounting period in which the services are rendered and the outcome of the contract can be estimated reliably. The company uses the percentage of completion method based on the actual service performed as a percentage of the total services to be provided.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
Motor vehicles	-	25% Straight line

Fully depreciated tangible assets are retained at cost less related accumulated depreciation until they are removed from service. In the case of disposals, assets and related depreciation are removed from the financial statements and the net amount, less proceeds from disposal, is charged or credited to the income statement.

Leasing and hire purchases

Tangible assets held under leasing and Hire Purchases arrangements which transfer substantially all the risks and rewards of ownership to the company are capitalised and included in the Balance Sheet at their cost or valuation, less depreciation. The corresponding commitments are recorded as liabilities. Payments in respect of these obligations are treated as consisting of capital and interest elements, with interest charged to the Profit and Loss Account.

JMR Pharma Engineering Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents include cash on hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are shown within borrowings in current liabilities on the statement of financial position.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation and deferred taxation

The company is managed and controlled in the Republic of Ireland and, consequently, is tax resident in Ireland. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case tax is also recognised in other comprehensive income or directly in equity respectively.

(i) Current tax

Current tax is calculated on the profits of the period. Current tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date.

(ii) Deferred tax

Deferred tax arises from timing differences that are differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

Deferred tax is provided in full on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred tax liability is settled.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised.

Current or deferred taxation assets and liabilities are not discounted.

Ordinary share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	14,125	13,988
Profit on disposal of intangible fixed assets	(8,026)	-
	<u> </u>	<u> </u>
4. Interest payable and similar expenses	2025	2024
	€	€
Interest	4,084	-
	<u> </u>	<u> </u>
5. Employees		

The average monthly number of employees, including directors, during the financial year was 2, (2024 - 0).

JMR Pharma Engineering Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 December 2025

6. Tangible assets

	Fixtures, fittings and equipment €	Motor vehicles €	Total €
Cost			
At 1 January 2025	10,137	55,950	66,087
Additions	-	56,500	56,500
Disposals	-	(55,950)	(55,950)
At 31 December 2025	<u>10,137</u>	<u>56,500</u>	<u>66,637</u>
Depreciation			
At 1 January 2025	10,137	27,976	38,113
Charge for the financial year	-	14,125	14,125
On disposals	-	(27,976)	(27,976)
At 31 December 2025	<u>10,137</u>	<u>14,125</u>	<u>24,262</u>
Net book value			
At 31 December 2025	<u>-</u>	<u>42,375</u>	<u>42,375</u>
At 31 December 2024	<u>-</u>	<u>27,974</u>	<u>27,974</u>
7. Debtors		2025	2024
		€	€
Trade debtors		31,577	24,326
Directors' current accounts		1	1
Taxation		1,513	-
		<u>33,091</u>	<u>24,327</u>
8. Creditors		2025	2024
Amounts falling due within one year		€	€
Trade creditors		2,078	1,525
Taxation		30,700	36,815
Accruals		40,000	-
		<u>72,778</u>	<u>38,340</u>
9. Creditors		2025	2024
Amounts falling due after more than one year		€	€
Finance leases and hire purchase contracts		<u>25,767</u>	<u>11,418</u>
Net obligations under finance leases and hire purchase contracts			
Repayable between one and five years		<u>25,767</u>	<u>11,418</u>

JMR Pharma Engineering Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 December 2025

10. Income Statement

	2025 €	2024 €
At 1 January 2025	17,727	17,693
Profit for the financial year	10,140	34
	<u>27,867</u>	<u>17,727</u>
At 31 December 2025	<u>27,867</u>	<u>17,727</u>

11. Capital commitments

The company had no capital commitments at the financial year-ended 31 December 2025.

12. Contingent liabilities

No contingent liabilities existed at 31 December 2025.

13. Directors' remuneration

	2025 €	2024 €
Remuneration	276,613	185,179
Pension contributions	40,000	22,000
	<u>316,613</u>	<u>207,179</u>

Key management are the directors. Key management remuneration is disclosed above

14. Controlling interest

The company is controlled by John Ridgway.

15. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 27 March 2026.